ALK and non-small cell lung carcinoma: Future research should not only explore trends in treatment patterns and outcomes for patients with ALK-positive NSCLC in real-world settings, but should also focus on addressing the technical and logistical challenges that hinder the widespread adoption of comprehensive genomic profiling.